Search clinical trials for: Ultratrace iobenguane I 131

Total 188 results

Molecular Insight Pharmaceuticals, Inc.

Completed

Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Molecular Insight Pharmaceuticals, Inc.

Completed

N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Neuroblastoma

United States
Molecular Insight Pharmaceuticals, Inc.

Withdrawn

Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma

Neuroblastoma

United States, Canada
Molecular Insight Pharmaceuticals, Inc.

Completed

ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

Pheochromocytoma | Paraganglioma | Carcinoid
Jubilant DraxImage Inc.

Available

Expanded Access Protocol Using 131I-MIBG

Neuroblastoma | Pheochromocytoma | Paraganglioma

United States
Jubilant DraxImage Inc.

Recruiting

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM)

Neoplasms | Neuroectodermal Tumors | Neuroblastoma

United States
Children's Hospital Medical Center, Cincinnati

No longer available

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Neuroblastoma | Pheochromocytoma | Paraganglioma

United States
Northwell Health
Cohen Children's Medical Center

Available

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

Neuroblastoma | Pheochromocytoma

United States
Molecular Insight Pharmaceuticals, Inc.

Approved for marketing

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Molecular Insight Pharmaceuticals, Inc.

Unknown

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Pheochromocytoma | Paraganglioma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Recruiting

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Neuroblastoma | Pheochromocytoma

United States
Cellectar Biosciences, Inc.

Recruiting

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Diffuse Large B Cell Lymphoma | Small Lymphocytic Lymphoma | Central Nervous System Lymphoma

United States, Australia, Czechia, Greece, Israel, Brazil, Finland, France, Spain, Turkey, United Kingdom
David Bushnell
VA Office of Research and Development

Completed

Combination Targeted Radiotherapy in Neuroendocrine Tumors

Neuroendocrine Tumors

United States
David Bushnell
National Cancer Institute (NCI); National Institutes of Health (NIH); Progenics...

Withdrawn

A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors (SPORE-3)

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor

United States
Cellectar Biosciences, Inc.
National Cancer Institute (NCI)

Recruiting

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

High-Grade Glioma

United States, Canada
Cellectar Biosciences, Inc.

Active, not recruiting

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | Pediatric Brain Tumor | DIPG | Pediatric Solid Tumor | Pediatric Lymphoma

United States, Australia, Canada
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
University of California, San Francisco

Approved for marketing

Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma

Pheochromocytoma | Paraganglioma

United States
Cellectar Biosciences, Inc.

Completed

Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned

Cancer

United States
Cellectar Biosciences, Inc.

Withdrawn

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Glioma

United States
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)

Differentiated Thyroid Carcinoma

Germany
New Approaches to Neuroblastoma Therapy Consortium
National Cancer Institute (NCI)

Completed

N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Neuroblastoma

United States
FDA Office of Orphan Products Development
Children's Hospital and Health Center

Completed

Liothyronine in Children With Single Ventricle Congenital Cardiac Malformations Undergoing the Fontan Procedure

Heart Defects, Congenital | Tricuspid Atresia
Molecular Insight Pharmaceuticals, Inc.

Terminated

Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma

Metastatic Melanoma

United States
University of Wisconsin, Madison
National Institute of Dental and Craniofacial Research (NIDCR); Cellectar Biosciences...

Active, not recruiting

CLR 131 Combined With Radiation for Head and Neck Cancer

Head and Neck Cancer

United States
TransMolecular

Unknown

131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma

Glioblastoma Multiforme | Malignant Glioma | Gliosarcoma | GBM | Anaplastic Astrocytoma | Oligo-Astrocytoma

United States
Emory University

Completed

Adolescent Idiopathic Scoliosis (AIS) Gold Standard for Blood Loss

Adolescent Idiopathic Scoliosis

United States
TransMolecular

Completed

131-I-TM-601 Study in Adults With Solid Tumors

Glioma | Melanoma | Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung Cancer | Prostate Adenocarcinoma | Primary Solid Tumors

United States
John Maris

Available

131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol

Neuroblastoma | Childhood Metastatic Pheochromocytoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

Neuroblastoma

United States
Children's Hospital Los Angeles
National Cancer Institute (NCI)

Completed

N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma

Neuroblastoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
GlaxoSmithKline

Completed

Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Hodgkin's Disease

United States
University of Michigan Rogel Cancer Center
GlaxoSmithKline

Active, not recruiting

Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma

Multiple Myeloma

United States
Centre Oscar Lambret
Novartis Pharmaceuticals; National Cancer Institute, France

Completed

Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma (MIITOP)

Neuroblastoma

France
University of Washington
National Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...

Completed

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
GlaxoSmithKline

Completed

Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab

Non-Hodgkin's Lymphoma

United States
GlaxoSmithKline

Completed

Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Completed

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma

United States
Y-mAbs Therapeutics

Terminated

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Peritoneal Cancer

United States
Rush University Medical Center
GlaxoSmithKline; Millennium Pharmaceuticals, Inc.

Terminated

A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

Follicular Lymphoma

United States
GlaxoSmithKline

Completed

Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP

Lymphoma, Non-Hodgkin
Memorial Sloan Kettering Cancer Center
Gustave Roussy, Cancer Campus, Grand Paris

Active, not recruiting

Lesion Dosimetry With 124-Iodine in Metastatic Thyroid Carcinoma

Thyroid Cancer

United States
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
GlaxoSmithKline

Completed

Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin
Cellectar Biosciences, Inc.

Completed

Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States

Search clinical trials for: Ultratrace iobenguane I 131

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations